Focused on creating novel therapies against diseases where the unmet medical need exists.
Our Pipeline
Clinical and Pre-Clinical Programs
Our Products
CiVi 030
CiVi 030 is an intravenous formulation of iloprost, a potent vasodilator and platelet inhibitor with anti-inflammatory and anti-fibrotic effects being developed for the treatment of digital ischemic episodes in people with Systemic Sclerosis (SSc).
CiVi 008
CiVi 008 is a third generation PCSK9 antisense molecule being developed as an oral treatment for hypercholesterolemia and the prevention of atherosclerotic cardiovascular disease.
Press Releases
Oct. 01, 2020
Investor Presentations
